BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 25398119)

  • 1. An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease.
    Balmes JR; Abraham JL; Dweik RA; Fireman E; Fontenot AP; Maier LA; Muller-Quernheim J; Ostiguy G; Pepper LD; Saltini C; Schuler CR; Takaro TK; Wambach PF;
    Am J Respir Crit Care Med; 2014 Nov; 190(10):e34-59. PubMed ID: 25398119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure-response analysis for beryllium sensitization and chronic beryllium disease among workers in a beryllium metal machining plant.
    Madl AK; Unice K; Brown JL; Kolanz ME; Kent MS
    J Occup Environ Hyg; 2007 Jun; 4(6):448-66. PubMed ID: 17474035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in understanding the biomolecular basis of chronic beryllium disease: a review.
    McCleskey TM; Buchner V; Field RW; Scott BL
    Rev Environ Health; 2009; 24(2):75-115. PubMed ID: 19658317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beryllium health effects in the era of the beryllium lymphocyte proliferation test.
    Maier LA
    Appl Occup Environ Hyg; 2001 May; 16(5):514-20. PubMed ID: 11370931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-DPB1 E69 genotype and exposure in beryllium sensitisation and disease.
    Crooks J; Mroz MM; VanDyke M; McGrath A; Schuler C; McCanlies EC; Virji MA; Rosenman KD; Rossman M; Rice C; Monos D; Fingerlin TE; Maier LA
    Occup Environ Med; 2022 Feb; 79(2):120-126. PubMed ID: 34535537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers.
    Van Dyke MV; Martyny JW; Mroz MM; Silveira LJ; Strand M; Fingerlin TE; Sato H; Newman LS; Maier LA
    Am J Respir Crit Care Med; 2011 Jun; 183(12):1680-8. PubMed ID: 21471109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcoidosis and chronic beryllium disease: similarities and differences.
    Mayer AS; Hamzeh N; Maier LA
    Semin Respir Crit Care Med; 2014 Jun; 35(3):316-29. PubMed ID: 25007084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization and chronic beryllium disease at a primary manufacturing facility, part 3: exposure-response among short-term workers.
    Schuler CR; Virji MA; Deubner DC; Stanton ML; Stefaniak AB; Day GA; Park JY; Kent MS; Sparks R; Kreiss K
    Scand J Work Environ Health; 2012 May; 38(3):270-81. PubMed ID: 21877099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease.
    Maier LA; Kittle LA; Mroz MM; Newman LS
    Am J Ind Med; 2003 Jun; 43(6):592-601. PubMed ID: 12768609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beryllium disease among construction trade workers at Department of Energy nuclear sites: A follow-up.
    Cloeren M; Dement J; Gaitens J; Hines S; Diaz L; Tembunde Y; Cranford K; Shorter J; Mosier T; Ringen K;
    Am J Ind Med; 2022 Sep; 65(9):708-720. PubMed ID: 35833586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease.
    Mroz MM; Maier LA; Strand M; Silviera L; Newman LS
    Am J Ind Med; 2009 Oct; 52(10):762-73. PubMed ID: 19681064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The beryllium lymphocyte proliferation test: Relevant issues in beryllium health surveillance.
    Stange AW; Furman FJ; Hilmas DE
    Am J Ind Med; 2004 Nov; 46(5):453-62. PubMed ID: 15490468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization and chronic beryllium disease at a primary manufacturing facility, part 1: historical exposure reconstruction.
    Virji MA; Park JY; Stefaniak AB; Stanton ML; Day GA; Kent MS; Kreiss K; Schuler CR
    Scand J Work Environ Health; 2012 May; 38(3):247-58. PubMed ID: 21850365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of an Exposure Response and Interaction With HLA-DPβ1 and DRβ1 Polymorphisms in the Development of Beryllium Toxicity in a High Beryllium Exposure Cohort.
    Widyaningsih V; Rosenman K; Reilly MJ; Wang L; Pathak DR; Gardiner JC; Rice C; Monos D; Rossman M
    J Occup Environ Med; 2020 Jan; 62(1):64-73. PubMed ID: 31743304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in identifying beryllium sensitization and disease.
    Middleton D; Kowalski P
    Int J Environ Res Public Health; 2010 Jan; 7(1):115-24. PubMed ID: 20195436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent chronic beryllium disease in residents surrounding a beryllium facility.
    Maier LA; Martyny JW; Liang J; Rossman MD
    Am J Respir Crit Care Med; 2008 May; 177(9):1012-7. PubMed ID: 18244954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the beryllium lymphocyte proliferation test using statistical process control.
    Cher DJ; Deubner DC; Kelsh MA; Chapman PS; Ray RM
    Inhal Toxicol; 2006 Oct; 18(11):901-10. PubMed ID: 16864408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beryllium sensitization and lung function among former workers at the Nevada Test Site.
    Rodrigues EG; McClean MD; Weinberg J; Pepper LD
    Am J Ind Med; 2008 Jul; 51(7):512-23. PubMed ID: 18459143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility.
    Schuler CR; Kent MS; Deubner DC; Berakis MT; McCawley M; Henneberger PK; Rossman MD; Kreiss K
    Am J Ind Med; 2005 Mar; 47(3):195-205. PubMed ID: 15712254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients.
    Müller-Quernheim J; Gaede KI; Fireman E; Zissel G
    Eur Respir J; 2006 Jun; 27(6):1190-5. PubMed ID: 16540500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.